CSF biomarkers β-amyloid, tau proteins and a-synuclein in the differential diagnosis of Parkinson-plus syndromes.

Differential diagnosis of Parkinson-plus patients (PSP, CBD, MSA) and Parkinson's disease (PD) patients is often not straightforward, particularly in atypical cases or at the initial stages of the diseases. Classic CSF biomarkers (amyloid-beta - Aβ42, tau protein - τT and phosphorylated tau protein - τP-181) are established biomarkers in the diagnosis of Alzheimer's disease (AD). CSF a-synuclein (α-syn) has emerged as a promising biomarker in patients with Parkinsonism. The aim of this study was to analyze the CSF biochemical profile of patients with Parkinsonism. We analyzed the CSF biomarker profile (Aβ42, τT, τP-181, α-syn) and all relevant ratios in 68 patients with Parkinsonism (19 PSP, 15 MSA, 17 CBD, 17 PD) and 18 controls, diagnosed by latest established diagnostic criteria. CBD patients exhibited elevated τT and decreased Aβ42 compared to the other groups. Five CBD, one PSP patient and one control had a typical AD CSF profile. After exclusion of these patients, the τT/Aβ42 ratio was significantly elevated in MSA patients compared to PD patients and provided excellent specificity and adequate sensitivity in their differential diagnosis. CSF biochemical profile analysis is important in distinguishing AD patients with a CBS phenotype from non-AD CBS patients. The τT/Aβ42 ratio is useful in the differential diagnosis of MSA from PD.

Constantinides VC ，Paraskevas GP ，Emmanouilidou E ，Petropoulou O ，Bougea A ，Vekrellis K ，Evdokimidis I ，Stamboulis E ，Kapaki E ... -  《-》

Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.

Chiasserini D ，Biscetti L ，Eusebi P ，Salvadori N ，Frattini G ，Simoni S ，De Roeck N ，Tambasco N ，Stoops E ，Vanderstichele H ，Engelborghs S ，Mollenhauer B ，Calabresi P ，Parnetti L ... -  《Alzheimers Research & Therapy》

Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders.

Hall S ，Öhrfelt A ，Constantinescu R ，Andreasson U ，Surova Y ，Bostrom F ，Nilsson C ，Håkan W ，Decraemer H ，Någga K ，Minthon L ，Londos E ，Vanmechelen E ，Holmberg B ，Zetterberg H ，Blennow K ，Hansson O ... -  《-》

Clinical value of CSF amyloid-beta-42 and tau proteins in Progressive Supranuclear Palsy.

Schirinzi T ，Sancesario GM ，Di Lazzaro G ，Scalise S ，Colona VL ，Imbriani P ，Mercuri NB ，Bernardini S ，Lang AE ，Pisani A ... -  《-》

Tau/α-synuclein ratio and inflammatory proteins in Parkinson's disease: An exploratory study.

No CSF or plasma biomarker has been validated for diagnosis or progression of PD. To assess whether the CSF and plasma levels of proteins associated with PD neuropathological inclusions and with neuroinflammation might have value in the diagnosis of PD or in relation to disease severity. CSF levels of α-synuclein, amyloid-ß1-42, total tau, and threonine-181 phosphorylated tau, as well as CSF and plasma levels of cytokines (interleukin-1ß, interleukin-2, interleukin, interferon-γ, and tumor necrosis factor α) were studied in 40 PD patients and 40 healthy controls. Plasma levels of cytokines were measured in 51 patients and 26 aditional controls. We also explored the Parkinson's Progression Markers Initiative data set as a replication cohort. CSF levels of α-synuclein, amyloid-ß1-42, and tumor necrosis factor α were lower in patients than in controls, and the total tau/α-synuclein, phosphorylated tau/α-synuclein, total tau/amyloid-ß1-42+α-synuclein, and phosphorylated tau/amyloid-ß1-42+α-synuclein ratios were higher in patients. The best area under the curve value was obtained for the phosphorylated tau/α-synuclein ratio alone (0.86) and also when this was combined with tumor necrosis factor α in CSF (0.91; sensitivity 92.9%, specificity 75% for a cut-off value of ≤ 0.71). Phosphorylated tau/α-synuclein and phosphorylated tau/amyloid-ß1-42+α-synuclein were higher in patients than in controls of the Parkinson's Progression Markers Initiative database. Plasma cytokines did not differ between groups, although interleukin-6 levels were positively correlated with UPDRS-I, -II, and -III scores. The CSF phosphorylated tau/α-synuclein ratio alone, and in combination with tumor necrosis factor α and plasma interleukin-6 levels, might serve as biomarkers to diagnose PD and monitor its severity. © 2017 International Parkinson and Movement Disorder Society.

Delgado-Alvarado M ，Gago B ，Gorostidi A ，Jiménez-Urbieta H ，Dacosta-Aguayo R ，Navalpotro-Gómez I ，Ruiz-Martínez J ，Bergareche A ，Martí-Massó JF ，Martínez-Lage P ，Izagirre A ，Rodríguez-Oroz MC ... -  《-》